Compass Therapeutics, Inc.
CMPXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Guggenheim | Michael Schmidt | $4.00(+223%) | $1.24 | StreetInsider |
| Sep 23, 2026 | Wedbush | $4.00(+223%) | $1.24 | StreetInsider | |
| Sep 22, 2026 | Wedbush | Robert Driscoll | $1.00(-19%) | $1.24 | StreetInsider |
| Jun 1, 2026 | Stifel Nicolaus | Stephen Willey | $6.00(+152%) | $2.38 | StreetInsider |
| Mar 5, 2026 | Jefferies | Maury Raycroft | $9.00(+63%) | $5.53 | StreetInsider |
| Feb 13, 2026 | Craig-Hallum | $15.00(+130%) | $6.52 | TheFly | |
| Feb 4, 2026 | Canaccord Genuity | $13.00(+102%) | $6.42 | TheFly | |
| Jan 6, 2026 | Raymond James | Sean McCutcheon | $9.00(+84%) | $4.89 | StreetInsider |
| Dec 3, 2025 | JMP Securities | Reni Benjamin | $10.00(+92%) | $5.22 | TheFly |
| Oct 6, 2025 | Compass Point | $10.00(+170%) | $3.70 | TheFly | |
| Apr 2, 2025 | Leerink Partners | Andrew Berens | $6.00(+255%) | $1.69 | TheFly |
| Sep 16, 2024 | Compass Point | Aydin Huseynov | $5.00(+203%) | $1.65 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Sep 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2026 |
| Wedbush | downgrade | Outperform →Neutral | Sep 23, 2026 |
| Craig-Hallum | maintain | Buy | Sep 23, 2026 |
| Citizens | maintain | Market Outperform | Sep 23, 2026 |
| Piper Sandler | maintain | Overweight | Aug 7, 2026 |
| Citizens | maintain | Market Outperform | Apr 28, 2026 |
| Canaccord Genuity | maintain | Buy | Apr 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 27, 2026 |
| D. Boral Capital | maintain | Buy | Apr 27, 2026 |
| Guggenheim | maintain | Buy | Mar 24, 2026 |
| D. Boral Capital | maintain | Buy | Jan 6, 2026 |
| D. Boral Capital | maintain | Buy | Nov 5, 2025 |
| Guggenheim | maintain | Buy | Aug 12, 2025 |
| D. Boral Capital | maintain | Buy | Aug 12, 2025 |
| Guggenheim | maintain | Buy | May 9, 2025 |
| D. Boral Capital | maintain | Buy | Apr 28, 2025 |
| Guggenheim | maintain | Buy | Apr 22, 2025 |
| D. Boral Capital | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| Leerink Partners | upgrade | Market Perform →Outperform | Apr 2, 2025 |
| Guggenheim | maintain | Buy | Apr 2, 2025 |
| D. Boral Capital | maintain | Buy | Apr 1, 2025 |
| D. Boral Capital | maintain | Buy | Feb 27, 2025 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.13 | $-0.11 | — | -$600.0K |
| May 5, 2026 | $-0.10 | $-0.10 | — | -$818.2K |
| Mar 5, 2026 | $-0.09 | $-0.10 | — | -$900.0K |
| Nov 5, 2025 | $-0.08 | $-0.14 | — | — |
| Aug 11, 2025 | $-0.14 | $-0.13 | — | — |
| May 8, 2025 | $-0.12 | $-0.12 | — | — |
| Feb 27, 2025 | $-0.11 | $-0.10 | — | — |
| Nov 12, 2024 | $-0.08 | $-0.11 | — | — |
News
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent cleavage of PD-1 receptors from T cells resulting in conversion of PD-1 positive T cells into PD-1 negative T cells. PD-1 receptor cleavage by CTX-10726 was only observed in the presence of VEGF-A, suggesting targeted activity in the tumor microenvironment.
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter. Details are as follows: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 1:30 PM ETWebcast Link: htt…
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanced biliary tract cancer (BTC) in the Journal of Clinical Oncology (JCO). The results are al…
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application (BLA) submission for tovecimig in patients with previously treated, advanc…